[go: up one dir, main page]

DK1654353T3 - Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf - Google Patents

Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Info

Publication number
DK1654353T3
DK1654353T3 DK04764266.5T DK04764266T DK1654353T3 DK 1654353 T3 DK1654353 T3 DK 1654353T3 DK 04764266 T DK04764266 T DK 04764266T DK 1654353 T3 DK1654353 T3 DK 1654353T3
Authority
DK
Denmark
Prior art keywords
dsm
applications
cell lines
tumor cell
acc2605
Prior art date
Application number
DK04764266.5T
Other languages
English (en)
Inventor
Steffen Goletz
Hans Baumeister
Marion Schlangstedt
Ute Schoeber
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of DK1654353T3 publication Critical patent/DK1654353T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04764266.5T 2003-08-18 2004-08-18 Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf DK1654353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03018576 2003-08-18
PCT/EP2004/009281 WO2005017130A2 (en) 2003-08-18 2004-08-18 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof

Publications (1)

Publication Number Publication Date
DK1654353T3 true DK1654353T3 (da) 2013-08-26

Family

ID=34178385

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764266.5T DK1654353T3 (da) 2003-08-18 2004-08-18 Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf

Country Status (9)

Country Link
US (2) US8017388B2 (da)
EP (1) EP1654353B1 (da)
CY (1) CY1114643T1 (da)
DK (1) DK1654353T3 (da)
ES (1) ES2425475T3 (da)
PL (1) PL1654353T3 (da)
PT (1) PT1654353E (da)
SI (1) SI1654353T1 (da)
WO (1) WO2005017130A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260426A1 (en) * 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
CN1926242B (zh) * 2004-02-13 2013-01-16 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP1900750A1 (en) * 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
KR101603632B1 (ko) 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
WO2012017925A1 (ja) 2010-08-02 2012-02-09 協和発酵キリン株式会社 物質の製造方法
BR112013003095B1 (pt) 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
US9611458B2 (en) 2010-12-27 2017-04-04 Kyowa Hakko Kirin Co., Ltd Method for preparing aqueous solution containing culture medium and chelating agent
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
JP7453151B2 (ja) 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
ATE243045T1 (de) * 1997-11-20 2003-07-15 Vical Inc Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
PT1529060E (pt) * 2002-07-22 2014-11-28 Glycotope Gmbh Processo para a produção de uma mucina imuno-estimuladora (muc1)
AU2003260426A1 (en) 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof

Also Published As

Publication number Publication date
ES2425475T3 (es) 2013-10-15
EP1654353B1 (en) 2013-05-22
PT1654353E (pt) 2013-08-23
WO2005017130A3 (en) 2005-06-23
SI1654353T1 (sl) 2013-09-30
EP1654353A2 (en) 2006-05-10
US20060292129A1 (en) 2006-12-28
PL1654353T3 (pl) 2013-11-29
US8017388B2 (en) 2011-09-13
US8283161B2 (en) 2012-10-09
WO2005017130A2 (en) 2005-02-24
US20110319590A1 (en) 2011-12-29
CY1114643T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
DK1506288T3 (da) Aktiveringsinduceret deaminase (aid)
DK1591446T3 (da) Thienopyrimidinforbindelser og anvendelse deraf.
DK1478648T3 (da) Phosphorholdige forbindelser og anvendelser deraf
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DE60311426D1 (de) Datentransferverfahren
DE60319430D1 (de) R- und fgfr-inhibitoren
IS8456A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1641822T3 (da) Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
FI20031133A0 (fi) Sulkimella varustettu liitin
DE60324067D1 (de) Informationsverarbeitungsgerät und -vorrichtung
FI20030594L (fi) Langaton tehon- ja tiedonsiirto
DK1654353T3 (da) Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
IS7594A (is) Laxófoxifen tafla og húðun hennar
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
IS8453A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1554250T3 (da) Hidtil ukendt lactamer og anvendelser deraf
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1359458T3 (da) Brillestel og hængselsenhed til anvendelse deri
FR2845832B1 (fr) Connecteur
DE60317400D1 (de) Verkleinerter Steckverbinder
IS8455A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
NO20030347D0 (no) Antenneelement og gruppeantenne
IS7783A (is) Flóð og fjöru-ker